Riskpilot← Back to searchSign inGet full accessNORITNIELSEN ApS PHARMASOURCE
APSDissolvedCVR 33266707Kompagnivej 7, 3. thBusiness and other management consultancy activities · NACE 7020Est. 20101 employees
Revenue 2024
DKK 375K
-58% vs 2023
EBITDA margin
-6.8%
-116% vs 2023
Equity ratio
42.4%
Financial strength
Net profit 2024
DKK 22K
-72% vs 2023
| Revenue | DKK 375K | -58% |
| EBITDA | DKK -26K | -116% |
| Net profit | DKK 22K | -72% |
| Total assets | DKK 425K | -24% |
| Equity | DKK 180K | +14% |
| Employees | 1 | — |
Legal name
NORITNIELSEN ApS PHARMASOURCE
CVR number
33266707
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
16. november 2010
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen
Address
Kompagnivej 7, 3. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.034 | 3.426 | 3.186 | 2.999 | 3.347 | 2.523 | 4.049 | 3.374 | 2.922 | 3.028 | 3.630 | 894 | 375 |
| Staff expenses | -1.651 | -2.382 | -2.350 | -1.468 | -1.449 | -1.451 | -2.100 | -1.881 | -1.864 | -1.937 | -1.691 | -731 | -400 |
| EBITDA | 383 | 1.045 | 837 | 1.531 | 1.898 | 1.072 | 1.948 | 1.493 | 1.058 | 1.091 | 1.938 | 163 | -26 |
| Depreciation & amort. | -0 | -0 | 6 | -7 | -9 | -12 | -10 | -9 | -5 | -0 | -0 | -0 | -0 |
| EBIT | 383 | 1.045 | 831 | 1.524 | 1.889 | 1.061 | 1.938 | 1.484 | 1.052 | 1.091 | 1.938 | 163 | -26 |
| Net financials | -0 | -0 | -0 | -4 | -1 | -1 | -2 | -13 | -12 | -17 | -16 | -1 | -1 |
| Profit before tax | 383 | 1.044 | 830 | 1.520 | 1.888 | 1.060 | 1.936 | 1.471 | 1.040 | 1.074 | 1.922 | 162 | -26 |
| Tax | 103 | 274 | 200 | 346 | 437 | 205 | 435 | 330 | 235 | 236 | 426 | 84 | -48 |
| Net profit | 280 | 771 | 630 | 1.174 | 1.452 | 855 | 1.502 | 1.140 | 805 | 837 | 1.496 | 78 | 22 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.060 | 2.214 | 1.739 | 2.934 | 3.239 | 2.784 | 4.180 | 3.566 | 3.015 | 3.134 | 2.967 | 563 | 425 |
| Equity | 427 | 997 | 1.128 | 1.802 | 2.253 | 1.909 | 2.610 | 2.451 | 2.055 | 2.093 | 2.089 | 158 | 180 |
| Long-term debt | 0 | 0 | 93 | 266 | 219 | 195 | 299 | 277 | 150 | 163 | 364 | 40 | 0 |
| Short-term debt | 633 | 1.217 | 505 | 866 | 728 | 681 | 1.229 | 821 | 790 | 859 | 512 | 365 | 245 |
| Total debt | 633 | 1.217 | 598 | 1.132 | 947 | 875 | 1.528 | 1.099 | 940 | 1.021 | 876 | 405 | 245 |
EBITDA margin
-6.8%
This company
15.8%
Market median
-143% vs market
20122024
Equity ratio
42.4%
This company
38.2%
Market median
+11% vs market
20122024
Return on equity
12.3%
This company
18.4%
Market median
+33% vs market
20122024
Net profit margin
5.9%
This company
8.1%
Market median
-27% vs market
20122024
Asset turnover
0.88×
This company
1.12×
Market median
+21% vs market
20122024
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LN Management | Management | 2010 | — | — |
LK Management | Management | 2010 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NORIT HOLDING ApS | Company | 50.0% | 50.0% | 2010 |
LISBETH K NIELSEN HOLDING ApS | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORITNIELSEN ApS PHARMASOURCE also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lisa Norit | Management | 0 companies |
| Lisbeth Karin Nielsen | Management | 0 companies |